Blueprint Medicines Corporation Stock News

Blueprint Medicines' (BPMC) lead drug, Ayvakit, approved to treat rare cancer and other rare diseases, has seen strong uptake since approval. However, stiff competition remains a concern.

Upgrades According to Wedbush, the prior rating for SciPlay Corp (NASDAQ:SCPL) was changed from Neutral to Outperform. In the first quarter, SciPlay showed an EPS of $0.18, compared to $0.21 from the

Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 0 2 0 1 L

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock?

Upgrades Citigroup upgraded the previous rating for FinVolution Group (NYSE:FINV) from Neutral to Buy. FinVolution Gr earned $0.30 in the first quarter, compared to $0.31 in the year-ago quarter. The

Keybanc cut Ambarella, Inc. (NASDAQ: AMBA) price target from $160 to $120. Ambarella shares fell 5% to $81.00 in pre-market trading. Piper Sandler reduced Salesforce, Inc. (NYSE: CRM) price target

Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 0 2 0 0 L

Here's why our roundtable thinks OptimizeRx, Affimed and Blueprint Medicines are all buys right now.

Blueprint Medicines' (BPMC) earnings meet estimates while revenue beat the same for the first quarter of 2022. Stock up.

Blueprint Medicines' (BPMC) earnings meet estimates while revenue beat the same for the first quarter of 2022. Stock up.

Blueprint Medicines Corporation (NASDAQ:BPMC ) Q1 2022 Earnings Conference Call May 3, 2022 8:30 AM ET Company Participants Jenna Cohen - Senior Director and Head of Investor Relations Kate Haviland -

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Acadia Announces FDA AdComm For Pimavanserin In Alzheimer's-Related Psychosis The FDA's Psychopharmaco

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 0% and 45.15%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?